Skip to content

Study · Randomized controlled trial · 2011

4 results

Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide.

Iversen P, Karup C, van der Meulen E, Tankó LB, Huhtaniemi I

Prostate cancer and prostatic diseases29 Mar 2011Cited by 12 (Europe PMC)

PMID21445092 (opens in a new tab)DOI10.1038/pcan.2011.11 (opens in a new tab)PepBankPUB-21445092
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, hot flushes began sooner with degarelix than leuprolide.

    In plain wordsIn prostate cancer patients, hot flushes began sooner with degarelix than leuprolide.

    Peptide
    Degarelix
    Outcome
    DecreaseHot flush onset
    Study

    n: not reported in source

    Comparator
    Leuprolide 7.5 mg monthly
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    240/80 or 240/160 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The onset of hot flushes was faster on degarelix versus leuprolide, and was accompanied by higher median hot flush scores during the first 3 months.
    3 context sentences
    Summary · context
    The aim of the study was to compare the onset, incidence and frequency/intensity of hot flushes during androgen-deprivation therapy with a gonadotropin-releasing hormone antagonist (GnRH) blocker versus an agonist using data from a randomized Phase 3 clinical trial.
    Summary · context
    In total, 610 prostate cancer patients received monthly degarelix (s.c., 240/80 mg, n=207, or 240/160 mg, n=202) or leuprolide (i.m., 7.5 mg, n=201) for 12 months.
    Summary · context
    Data on hot flushes was collected as self-reported adverse events and in a subgroup of 254 patients with electronic diaries.
  2. 02HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, median hot flush scores were higher with degarelix than leuprolide during the first 3 months.

    In plain wordsIn prostate cancer patients, median hot flush scores were higher with degarelix than leuprolide during the first 3 months.

    Peptide
    Degarelix
    Outcome
    IncreaseMedian hot flush score during first three months
    Study

    n: not reported in source

    Comparator
    Leuprolide 7.5 mg monthly
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    240/80 or 240/160 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The onset of hot flushes was faster on degarelix versus leuprolide, and was accompanied by higher median hot flush scores during the first 3 months.
    3 context sentences
    Summary · context
    The aim of the study was to compare the onset, incidence and frequency/intensity of hot flushes during androgen-deprivation therapy with a gonadotropin-releasing hormone antagonist (GnRH) blocker versus an agonist using data from a randomized Phase 3 clinical trial.
    Summary · context
    In total, 610 prostate cancer patients received monthly degarelix (s.c., 240/80 mg, n=207, or 240/160 mg, n=202) or leuprolide (i.m., 7.5 mg, n=201) for 12 months.
    Summary · context
    Data on hot flushes was collected as self-reported adverse events and in a subgroup of 254 patients with electronic diaries.
  3. 03HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, overall hot flush incidence did not differ significantly between degarelix and leuprolide over 12 months.

    In plain wordsIn prostate cancer patients, hot flush incidence did not differ significantly between degarelix and leuprolide over 12 months.

    Peptide
    Degarelix
    Outcome
    No significant changeOverall hot flush incidence
    Study

    n: not reported in source

    Comparator
    Leuprolide 7.5 mg monthly
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    240/80 or 240/160 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    However, there were no significant differences in overall incidence rates and median hot flush scores over the entire 12 months.
    3 context sentences
    Summary · context
    The aim of the study was to compare the onset, incidence and frequency/intensity of hot flushes during androgen-deprivation therapy with a gonadotropin-releasing hormone antagonist (GnRH) blocker versus an agonist using data from a randomized Phase 3 clinical trial.
    Summary · context
    In total, 610 prostate cancer patients received monthly degarelix (s.c., 240/80 mg, n=207, or 240/160 mg, n=202) or leuprolide (i.m., 7.5 mg, n=201) for 12 months.
    Summary · context
    Data on hot flushes was collected as self-reported adverse events and in a subgroup of 254 patients with electronic diaries.
  4. 04HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, median hot flush scores did not differ significantly between degarelix and leuprolide over 12 months.

    In plain wordsIn prostate cancer patients, median hot flush scores did not differ significantly between degarelix and leuprolide over 12 months.

    Peptide
    Degarelix
    Outcome
    No significant changeMedian hot flush score over twelve months
    Study

    n: not reported in source

    Comparator
    Leuprolide 7.5 mg monthly
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    240/80 or 240/160 mg monthly · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    However, there were no significant differences in overall incidence rates and median hot flush scores over the entire 12 months.
    3 context sentences
    Summary · context
    The aim of the study was to compare the onset, incidence and frequency/intensity of hot flushes during androgen-deprivation therapy with a gonadotropin-releasing hormone antagonist (GnRH) blocker versus an agonist using data from a randomized Phase 3 clinical trial.
    Summary · context
    In total, 610 prostate cancer patients received monthly degarelix (s.c., 240/80 mg, n=207, or 240/160 mg, n=202) or leuprolide (i.m., 7.5 mg, n=201) for 12 months.
    Summary · context
    Data on hot flushes was collected as self-reported adverse events and in a subgroup of 254 patients with electronic diaries.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.